Show simple item record

dc.rights.licenseRestricted to current Rensselaer faculty, staff and students. Access inquiries may be directed to the Rensselaer Libraries.
dc.contributorIsaacson, David
dc.contributorBelfort, Georges
dc.contributorHolmes, Mark H.
dc.contributorZuker, Michael
dc.contributor.authorRosenthal, Joseph H.
dc.date.accessioned2021-11-03T08:28:25Z
dc.date.available2021-11-03T08:28:25Z
dc.date.created2015-10-01T11:34:28Z
dc.date.issued2015-08
dc.identifier.urihttps://hdl.handle.net/20.500.13015/1536
dc.descriptionAugust 2015
dc.descriptionSchool of Science
dc.description.abstractAmyloid-beta peptides have long been associated with the pathology of Alzheimer's disease. A two-pronged approach to investigating amyloid-beta in the context of Alzheimer's disease is presented with an amyloid aggregation reaction model and a macrolevel model of a potentially disease-modifying treatment for Alzheimer's disease.
dc.description.abstractAmyloid-beta oligomers are believed to be one of the principle neurotoxic species in Alzheimer's disease. A kinetic model was constructed to elucidate the aggregation of these toxic oligomers and the fibrils that they eventually form. The effects of osmolytes and polymers on amyloids are explored to better relate results to in vivo conditions. The kinetics of Alzheimer's-relevant amyloid-beta mutants are also modeled.
dc.description.abstractAmyloid-beta removal through apolipoprotein E binding has been shown to be up-regulated by bexarotene, a drug approved by the U.S. Food and Drug Administration for treating a class of non-Hodgkin's lymphoma. A mathematical model was constructed to simulate amyloid-beta production throughout the lifespan of diseased mice and demonstrate the efficacy of bexarotene treatments in reducing amyloid-beta load. Both aspects of the model are based on and consistent with previous experimental results. Low dosages of bexarotene were unable to stem cell death, but dosages at and above a critical concentration were found to recover healthy brain cells. Early treatment was shown to have significantly improved efficacy. Relevance with respect to bexarotene-based amyloid-beta-clearance mechanism and direct treatment for Alzheimer's disease is emphasized.
dc.language.isoENG
dc.publisherRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofRensselaer Theses and Dissertations Online Collection
dc.subjectMathematics
dc.titleMathematical models of amyloid-beta production, aggregation, and treatment in Alzheimer's disease
dc.typeElectronic thesis
dc.typeThesis
dc.digitool.pid176744
dc.digitool.pid176745
dc.digitool.pid176746
dc.rights.holderThis electronic version is a licensed copy owned by Rensselaer Polytechnic Institute, Troy, NY. Copyright of original work retained by author.
dc.description.degreePhD
dc.relation.departmentDept. of Mathematical Sciences


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record